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Abstract 
Background: Globally, it is known that HIV‑infected pregnant women are prone to depressive symptoms. Research 
evidences also suggest that nutrient deficiencies may enhance the depressive illness, and that fish oil omega‑3 fatty 
acids may alleviate the depressive symptoms. The aim of this study was to assess the effect of fish oil omega‑3 eicosa‑
pentaenoic acid‑rich supplements on depressive symptoms among HIV‑seropositive pregnant women.
Trial design: A randomized double‑blinded controlled trial with two parallel groups was conducted. The interven‑
tion group received fish oil omega‑3 of 3.17 g (eicosapentaenoic acid = 2.15 g; docosahexaenoic acid = 1.02 g) per 
day for 8 weeks, while the control group received soybean oil for a similar period.
Method: Participants were HIV‑seropositive pregnant women who were enrolled in prevention of mother‑to‑child 
transmission programs and attending antenatal clinics at selected Nairobi city county’s health facilities. Recruitment 
was done from health records of HIV‑infected pregnant women. Data analysis followed per‑protocol analysis. Partici‑
pants who completed the 8‑week trial were included in the analysis of covariance statistical model with omega‑3 as 
main effect. The covariates in the change in BDI‑II depressive symptom score outcome were baseline characteristics 
and nutrient adequacy.
Results: 282 participants were recruited 109 randomized to fish oil, and 107 to soybean oil. Completion rate was 
86/109 (78.9%) and 96/107 (89.7%) respectively. At the end of week‑8 of follow up most participants in both arms 
had mild depressive symptoms 82/86 (95.3%) in the Fish oil group and 94/96 (97.9%) in the Soybean oil group. The 
difference in effect between the intervention and control group was not statistically significant (1.01 (95% CI − 0.58 to 
2.60), p = 0.21).
Conclusion: Fish oil omega‑3 with a daily dosage of 3.17 g (eicosapentaenoic acid = 2.15 g; docosahexaenoic 
acid = 1.02 g) appears to provide no added benefit in reduction of the symptoms of depression in HIV‑infected preg‑
nant women.
Trial Registration Clinical Trial Registry: NCT01614249. Registered on June 5, 2012. https ://clini caltr ials.gov/ct2/show/
NCT01 61424 9
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Introduction
During pregnancy, women may experience at least one 
episode of minor or major depression referred to as 
perinatal or maternal depression. The depression in 
pregnant women is, however, often under-diagnosed, 
undetected and missed out due to lack of routine screen-
ing [1]. Research findings on depression in pregnancy 
indicate that 20–40% of pregnant women are depressed 
[2–4]. Globally, it is also known that human immunode-
ficiency virus (HIV)-infected pregnant women are prone 
to depression [5–8]. The depression symptoms in HIV-
infected pregnant women may be due to the effects of 
pregnancy, HIV infection or a combination of both preg-
nancy and HIV infection. Some symptoms of depression 
such as fatigue, mood disorders, changes in appetite, or 
changes in sleeping pattern have been known to overlap 
with the symptoms present in pregnancy, HIV infection 
or due to side effects of HIV medication [9]. Among HIV-
positive pregnant women in Sub-Saharan Africa, Smith 
Fawzi, Kaaya [10] reported a prevalence of elevated 
depressive symptoms of 42.4% in Tanzania. Manikkam 
and Burns [11] also established a depression prevalence 
of 38.5% among HIV-infected pregnant women in Kwa-
Zulu-Natal, while Rochat, Richter [12] reported a preva-
lence of 47% from rural South Africa and Kwalombota 
[13] reported a high prevalence of major depression of 
85% from Zambia. These research evidences suggest that 
depression in HIV-infected pregnant women is a public 
health problem.
Evidences suggest that nutrient deficiencies may 
enhance the depressive illness and in pregnancy and 
HIV infection, nutrients’ demand is higher than nor-
mal due to increased need by the developing fetus in the 
context of nutrient deficiencies that result from reduced 
food intake, impaired nutrient absorption and altered 
metabolism due to the HIV status [14]. Yet, inadequate 
and inappropriate dietary intake has been reported glob-
ally among pregnant women. For example, in the United 
States of America [15], Canada [16], Europe [17, 18], 
Australia [19], India [20] and Africa [21], studies indicate 
that micronutrients and omega-3 fatty acid intake values 
are below the recommended levels for normal healthy 
life. It is also globally known that fish oil omega-3 fatty 
acids may alleviate the depressive symptoms in preg-
nancy [22–25]. Inconsistencies exist in several previous 
studies [25–28]. These variations could be attributed to 
differences in the ratio of omega-3 long-chain fatty acids 
of eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), depression assessment tools, intervention dura-
tion or physiological status of study participants, which 
varies by study. Although omega-3 DHA is recognized as 
an essential structural component of the cell membranes 
in the central nervous system [29], some evidence suggest 
that omega-3 EPA may be more beneficial in reduction 
of depression than DHA, based on its anti-inflammatory 
effects of the metabolic products of eicosanoids and its 
oxidized derivatives as well as its efficacy at reducing the 
inflammatory cytokines [30, 31]. These metabolic prod-
ucts of EPA are important in controlling the cellular 
inflammation in the CNS that may manifest as depres-
sive symptoms. A higher proportion of omega-3 EPA 
than DHA in the fish oil omega-3 supplement at a higher 
ratio has, therefore, been presumed to be more benefi-
cial in reduction of depressive symptoms [31, 32]. This 
is demonstrated in the study by Freeman and colleagues 
[22] who used a lower omega-3 fatty acid ratio of 1.1 g/
day EPA and 0.8  g/day DHA and found no significant 
benefit of omega-3 over placebo, and, Su and colleagues 
[25] who reported a significant reduction in depression 
with higher omega-3 content of 2.2 g/day EPA and 1.2 g/
day DHA.
There is paucity of published research on the effect of 
fish oil omega-3 on depression among the HIV-infected 
pregnant women. Yet, while depression is common in 
pregnancy, HIV infection is also a factor that induces 
depression, a combination of the two may cause severe 
depression effects hitherto unaddressed. In HIV infec-
tion, opportunistic infections in the central nervous 
system may affect the patients cognitive, motor and 
behavioural functioning, and, manifest as psychiatric 
disturbances including depression [33]. The depression 
in HIV-infected pregnant women may also negatively 
impact on the progression of HIV disease [5, 8] and may 
adversely affect the quality of life and adherence to HIV/
AIDS medication regimens [10, 34, 35]. The studies that 
have been conducted on omega-3 fatty acids in HIV 
infection have focused on the effect on triglycerides and 
cluster of differentiation 4 (CD4) cell count. For example, 
omega-3 fatty acid supplementation has been shown to 
reduce triglyceride levels in patients receiving antiretro-
viral [36, 37]. Omega-3 fatty acid supplementation has 
also been shown to increase CD4 cell count as demon-
strated [38, 39]. To our knowledge, therefore, no previ-
ous studies had been undertaken on the effect of fish 
oil omega-3 fatty acids on depressive symptoms among 
HIV-infected pregnant women.
The research hypothesis for our study was derived 
from the evidence that omega-3 can alleviate symp-
toms of depression [25, 26, 28, 40–42]. If omega-3 EPA 
fatty acid is the most important compound in alleviat-
ing depressive symptoms [25, 26, 28], then depressed 
individuals taking fish oil omega-3 supplements should 
experience a change in severity of their depressive 
symptom condition. A 50.0% reduction in depres-
sive symptom scores after 8 weeks of supplementation 
with fish oil (EPA = 2.2  g/day; DHA = 1.2  g/day) had 
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been earlier reported [25]. Sources of omega-3 fatty 
acids have also influenced the designing of studies on 
fish oil omega-3 and depression. Whereas fish oil con-
tains long-chain omega-3 EPA and DHA fatty acids, 
plant-based edible oils like soybean contain short-
chain omega-3 ALA which must be metabolized after 
consumption to EPA and DHA in the body, hence the 
choice of soybean oil for the control group. Most clini-
cal trials on long-chain omega-3 EPA and DHA fatty 
acids have also used plant-based oils such as olive oil, 
soybean, canola, palm oil, corn oil or sunflower [43] for 
the control group in fish oil omega-3 interventions.
Methods
Participants
The study population was HIV-positive pregnant 
women enrolled in the Prevention of Mother to Child 
Transmission (PMTCT) of HIV/AIDS programs and 
attending antenatal clinics (ANC) at Nairobi City 
County’s health facilities of Riruta, Mathare North, 
Kariobangi North and Kayole-II Sub-district Hospital. 
All HIV-seropositive pregnant women were eligible 
to participate in the study if they had known CD4 cell 
count of not more than 500 cells/µl, were on antiretro-
viral therapy (ART) and were in their second trimester 
of pregnancy at 14–27  weeks. Only those who con-
sented to participate by signing the consent form and 
had at least 14 scores on Beck Depression Inventory 
Second Edition (BDI-II) scoring questionnaire were 
enrolled.
Participants were excluded from the study if they 
were underweight with a mid-upper arm circumference 
(MUAC) less than 22 cm and overweight with MUAC of 
more than 33 cm. They were also excluded if they had a 
medical history of use of a blood thinning medication/
anti-clotting medication for health conditions like liver 
problem, varicose veins, peptic ulcers; or use of Vitamin 
K supplement since omega-3 may increase the effects of 
these medications. Those who had used antidepressant 
medications 2  weeks prior to the study or were on dia-
betic medication to lower blood sugar were also excluded 
from the study.
Ethical approval to conduct the study was obtained 
from the Kenyatta National Hospital/University of 
Nairobi Ethical Review Committee (KNH/UoN-ERC, 
P266//6/2011), the Ministry of Education, Research and 
Technology (NCST/RRI/12/1/MED011/167) and from 
the Pharmacy and Poisons Board of Kenya (PHD/MOH/
R1/101/2011/ac). Furthermore, only those who agreed 
to participate by signing the consent forms after receiv-
ing the relevant information about the study from the 
research team were enrolled in the study.
Interventions
The intervention group received three soft gels of fish 
oil omega-3 fatty acid for each day, each containing 
more EPA (0.715 grams) than DHA (0.340 grams). For 
the intervention group, therefore, the total daily intake 
of omega-3 fatty acids from the three fish oil soft gels 
was 3.17 grams (EPA = 2.15 grams per day; DHA = 1.02 
grams per day) for each participant. The control group 
received three soft gels of soybean oil per day, each 
containing saturated fatty acids (0.178 grams), mono-
unsaturated fatty acids (0.299 grams) and polyunsatu-
rated fatty acids (0.985 grams) with traces of EPA (0.115 
grams). Both the fish oil omega-3 supplements and soy-
bean oil soft gels were provided by Innovix Pharma Inc, 
California, manufacturers of OmegaVia fish oil prod-
ucts. These products were both similar in shape, color 
and taste.
Participants carried the fish oil omega-3 and soybean 
oil soft gels home to take orally, one three times per day: 
in the morning, mid-day and in the evening after meals 
for a period of 8 weeks. The participants received the trial 
product supplies to last of them for 2 weeks, after which 
they came to the sites for follow-up visits for face-to-face 
monitoring of side effects and compliance as well as re-
supply of the products. Each participant was encouraged 
to use the research cell-phone contact on the container 
for the products to contact the research team whenever 
necessary. Regular cell-phone contacts were established 
with each participant immediately after enrolment in 
the study. Participants were also contacted on the cell-
phone details they provided during recruitment at least 
two times a week to monitor intake of the soft gels and 
to remind them of the next visit to the study site. Further 
confirmation as to whether all the soft gels were swal-
lowed was done during the bi-weekly face-to-face visits 
for re-supply of trial products and data collection. During 
these visits, each participant was asked whether she had 
any soft gel left in her container at home, and the num-
ber. Participants were expected to have remained with 
only one or two soft gels in their last container before 
starting the next re-supply container. Any participant, 
who reported more soft gels left in her container than 
the expected number, was required to give reasons for 
non-completion. Participants who had soft gels for 5 days 
or more were dropped out of the study for non-compli-
ance. Those who were non-compliant and had depressive 
symptoms were referred to the doctor in the same health 
facilities for medical attention and counseling.
Objective and hypothesis
The objective of this study was to determine the effect 
of fish oil omega-3 EPA-rich supplements on BDI-II 
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depressive symptom scores among HIV-seropositive 
pregnant women.
We hypothesized that there is a difference in the mag-
nitude of change in depressive symptom scores of at least 
20% as measured by BDI-II scale among HIV-seroposi-
tive pregnant women with depressive symptoms taking 
fish oil omega-3 EPA-rich supplements than the control 
group taking soybean oil soft gels whose alphalinoleic 
acid are minimally metabolized to EPA [44, 45]. The null 
hypothesis of this study was that there is no difference in 
the magnitude of change in BDI-II scores between HIV-
seropositive pregnant women with depressive symptoms 
taking fish oil omega-3 EPA-rich supplements and the 
control group taking soybean oil soft gels.
Outcomes
The primary outcome variable of the study was the 
change in depressive symptom scores between base-
line scores and the scores after 8 weeks as measured by 
BDI-II scale. The Beck Depression Inventory Second 
Edition (BDI-II) Scale is a 21-item scoring tool which 
measures the existence and severity of symptoms of 
depression. Each of the 21 items on BDI-II tool repre-
sents a depressive symptom. The symptoms are each 
scored on a 4-point Likert scale of 0–3 (0 = symptom is 
absent; 3 = symptom is severe). Scores for each symptom 
was added up to obtain the total scores for all 21 items, 
which are interpreted as follows: Scores of 0–13: minimal 
depression; 14–19: mild depression; 20–28: moderate 
depression and 29–63: severe depression.
This outcome is similar to what Su and colleagues used 
in their study from Taiwan [25]. The quality of this out-
come variable was enhanced in our study in several ways. 
First, the intervention allocation ratio of 1:1 used ensured 
a balance in allocation and minimization of within-group 
variability. Second, the participants and those adminis-
tering the trial, including the principal investigator were 
blinded to the trial allocation. Third, standard operat-
ing procedures were developed and used as step-by-step 
guidelines to ensure uniformity in intervention imple-
mentation and data collection as per the research pro-
tocol. Fourth, the research team was trained on data 
collection tools and principles of good clinical practices 
(GCP). They undertook the GCP online course at East 
African Consortium for Clinical Research (EACCR) 
website http://www.eaccr .org/nodes /train ing/. Fifth, a 
Data and Safety Monitoring Board (DSMB) was consti-
tuted to monitor the safety and treatment efficacy of the 
omega-3 supplements during the clinical trial period. The 
DSMB was an independent group of experts comprising 
of a pharmacist, gynecologist, biostatistician and a psy-
chiatrist. Sixth, dietary intake data for locally available 
omega-3 rich foods were collected and controlled for as 
a potential confounder in the statistical analysis. Seventh, 
participants were regularly monitored for compliance in 
taking the trial products.
Sample size
A sample size of 91 women per study group gave an 85% 
power to detect as statistically significant at 5% level 
(α = 0.05), a true difference of four scores in the mean 
depressive symptom scores between women given fish oil 
omega-3 EPA-rich supplements and women given soybean 
oil, assuming a within-group standard deviation of nine 
in depressive symptom scores. Assuming that the mean 
depressive symptom scores after 8  weeks in the control 
group was 20 scores; a decrease of four units corresponded 
to a 20% change in the depressive symptom scores.
The sample size was determined based on an assumption 
of omega-3 intervention difference of lowering depressive 
symptom scores by an estimated 20% as measured by Beck 
Depression Inventory, Second Edition (BDI-II) Scores. 
Su and colleagues reported a 50% reduction in depressive 
symptom scores after 8 weeks of intervention with fish oil 
omega-3 [25]. A change of 20% would be a change of at 
least 4 units. The sample size was adjusted for a 10% non-
response due to drop-outs and losses to follow-ups; the 
following formula was used to calculate the final adjusted 
sample size: n* = n/(1 − q), where n* = adjusted sample size, 
n = sample size before adjusting, and q = the proportion 
expected for non-response [46], estimated at 10%. When 
adjusted for the 10% non-response due to drop-outs, a total 
of 200 participants with at least mild depressive symptoms 
[47] were enrolled in the study, with 100 participants ran-
domized in each of the study groups. However, during the 
trial, 16% of the study participants dropped out instead 
of the planned 10%. An additional 16 participants were, 
therefore, recruited with approval from Kenyatta National 
Hospital/University of Nairobi Ethical Review Committee 
(KNH/UoN-ERC), the institutional review board. Hence, a 
total of 216 participants were enrolled in the study, 109 on 
fish oil omega-3 intervention and 107 on soybean soft gel 
control arm.
Randomization procedure
Randomization allocation sequence was computer gener-
ated. Block randomization of four fixed blocks was used, 
with a 1:1 allocation ratio used to achieve balance in allo-
cating the intervention to participants in the four study 
sites and to reduce within-group variability. For every block 
of four participants, two were allocated to each interven-
tion group. The four blocks used were consistent with the 
four study sites of Kariobangi, Riruta, Mathare and Kay-
ole health centers. Six possible balanced combinations of 
assignment of either fish oil or soybean oil group in four 
blocks were computer generated as: BBAA BABA, BAAB, 
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ABBA, ABAB and AABB. Participants were allocated to 
each group by randomly selecting one of the six combina-
tions and assigning them an identification code according 
to the specified sequence as described by Efird [48].
Randomization allocation concealment
Allocation concealment refers to the technique used to 
implement the randomization sequence [49] by protect-
ing the randomization list and allocation codes such that 
the allocated intervention is not known until the study 
is un-blinded. We achieved the randomization alloca-
tion concealment in this study by involving someone who 
did not participate in recruitment, enrolment, data col-
lection and monitoring or data management to allocate 
the intervention to participants using plastic bottles. The 
plastic bottles were identical, opaque, securely sealed and 
sequentially numbered according to the study randomi-
zation sequence generated. The randomization sequence 
was concealed by the independent statistician until 
the interventions were assigned. Hence, only the inde-
pendent statistician who generated the randomization 
sequence and the person who allocated the intervention 
were not blinded to the study.
Randomization implementation
The randomization allocation sequence was generated by 
an independent statistician who was not involved in the 
study to ensure allocation concealment of the interven-
tion. Participants were recruited in the study by mentor 
mothers of mother2mothers (m2m) non-governmental 
organization who provided peer education and psycho-
social support in PMTCT. They were assigned to either 
of the trial arms by the data collection team soon after 
enrollment and completion of the study questionnaires 
to minimize dropouts, which might have occurred if 
enrolled participants exceeded gestation age or gave birth 
before randomization.
Blinding
This study was blinded to the participants and those 
administering the trial, including the principal investiga-
tor, were unaware of the intervention/treatment alloca-
tion. Specifically, the following individuals involved in 
the trial activities were blinded from the trial: principal 
investigator, study participants, health facility personnel, 
and research assistants and data clerk handling the data. 
Un-blinding of the trial products was performed after 
completion of data collection, data entry and preliminary 
analysis by the independent statistician who had gener-
ated the randomization sequence. The un-blinding was 
done in the presence of the researcher, and witnessed by 
at least one academic supervisor and the director of the 
school. This procedure of un-blinding the trial completely 
eliminated any source of bias during administration of 
the study products.
Statistical methods
The primary outcome variable, change in BDI-II depres-
sive symptom scores, was computed as suggested by 
Jamieson [50] in his article on analysis of covariance 
(ANCOVA) with difference scores as follows: Post-inter-
vention BDI-II scores (at week 4 or week 8) minus base-
line BDI-II scores (at week 0). The change in BDI-II scores 
at weeks four (mid-study) and eight (end of study) were 
tested for normality and summarized as mean values 
with standard deviations (SD), reporting 95% confidence 
interval levels (95% CI). The magnitude and difference in 
change in BDI-II depressive symptom scores were com-
pared between the two study groups by Student t test. 
Before adjusting for baseline covariates, simple linear 
regression model was fitted to determine the variabil-
ity in change in BDI-II scores that was explained by the 
intervention. The level of significance for all the infer-
ential tests was at 5%. Regression to the mean effect by 
any suspected extreme values was controlled by ran-
domization at the study design stage and by analysis of 
covariance (ANCOVA) model during data analysis. The 
ANCOVA adjusts each participant’s follow-up measure-
ment according to their baseline measurement [51]. The 
analysis followed per-protocol analysis approach, where 
participants who did not complete the trial were not 
included for the primary outcome analysis at the end of 
the study. Those who dropped out of the study before 
the end of 4  weeks after enrolment were not included 
in the mid-study analysis. Similarly, all participants who 
dropped out of the study before the end of the trial at 
8 weeks were not included in the final data analysis.
The intervention effect was compared between the 
two groups by fitting the ANCOVA regression model. 
The model included change in BDI-II scores after inter-
vention, all the baseline characteristics and intervention 
arms. All baseline characteristics were included in the 
model as covariates to adjust for any possible variations 
at baseline before randomization into fish oil interven-
tion group or soybean control group, and to control for 
regression to the mean. Bivariate and multiple linear 
regression analysis were used to determine which vari-
ables were key determinants of BDI-II depressive symp-
tom scores. Heteroskedasticity due to differences in 
variance in the errors across observations was controlled 
by robust standard errors analysis in the regression 
model. The presence of interaction between the covari-
ates (predictor variables) that were found to be signifi-
cantly associated with the change in BDI-II scores in the 
ANCOVA model was tested. There was no interaction 
between the predictor variables.
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Results
Participant flow and baseline characteristics
The participant flow throughout the study is as shown in 
Fig.  1. We recruited 282 pregnant women who met the 
inclusion criterion of HIV-seropositive with CD4 count 
of not more than 500 cells/mm3and gestation of 14 to 
27 weeks of pregnancy. The study was conducted from July 
2012 to August 2013. After screening for enrolment, 66 
of the 282 were excluded due to exclusion criteria of mid-
upper arm circumference (MUAC) measurement of more 
than 33 cm (n = 1) and depressive symptoms scores being 
less than 14 (n = 65). During the trial, 16.0% (34/216) of the 
participants dropped out instead of the planned 10%. An 
additional 16 participants were, therefore, recruited with 
approval from the institutional ethical review board, KNH/
UoN-Ethical Review Committee. Hence, a total of 216 par-
ticipants were enrolled and randomly assigned into the two 
study arms: 109 received fish oil omega-3 and 107 received 
soybean oil soft gels, each for 8 weeks. A total of 182 par-
ticipants completed the 8-week study period: 86 from the 
omega-3 fish oil group and 96 from soybean oil group.
Overall completion rate was 84.3% (182/216) for all the 
enrolled participants. The completion rates were 78.9% 
(86/109) and 89.7% (96/107) for fish oil omega-3 and soy-
bean oil arms, respectively. The difference in completion 
between the two groups was, however, not significant at the 
end of study (X2(1) = 1.64; p value = 0.20), and did not sig-
nificantly influence the change in BDI-II depressive symp-
tom scores in fish oil (0.41 (95% CI − 4.49 to 5.32), p = 0.87) 
and soybean oil (− 3.21 (95% CI − 13.18 to 6.76), p = 0.52) 
groups. A total of 34 of them dropped out; 23 from omega-3 
arm and 11 from the soybean arm, respectively. Among 
the 34 participants who did not complete the 8-week study 
period, 21 of them had traveled to the rural homes, nine 
failed to return for bi-weekly re-supply for unknown rea-
sons and four of them gave birth before the end of the trial.
Characteristics of participants at baseline
Demographic and socio‑economic and characteristics 
of participants
The participants’ characteristics of demographic, socio-
economic, health and HIV status at baseline are shown in 
Received Soybean oil 
(n=107)
Recruited Participants (N=282)
HIV-seropositive pregnant women with CD4 count of not more 
than 500 and gestation of 14-27 weeks at PMTCT 
Enrolled Participants (N=216):
Baseline data collected on 216 participants
Received Fish oil omega-3 
(n=109)
Monitoring every 2weeks; Data collected at 
4 weeks (n=92)
Monitoring every 2 weeks; Data collected at 
4 weeks (n=98)
Excluded as per exclusion criteria (N=66)
1. MUAC less than 22 cm and more than 
33 cm(n= 1)
2. BDI-II Scores less than 14 (n= 65)
Completed the trial period of 8 weeks and analyzed 
(n=86).
Drop-outs, did not 
complete the trial 
(n=23)
Drop-outs, did not 
complete the trial 
(n=11)
Completed the trial period of 8 weeks and data analyzed 
(n=96).
Fig. 1 Participants’ distribution and flow during the trial based on the Consolidated Standards of Reporting Trials. The participants’ distribution and 
flow during the trial based on the Consolidated Standards of Reporting Trials [52]. It indicates total number of study participants who were recruited 
(N = 282), excluded from enrolment based on exclusion criteria (N = 66), enrolled for the 8‑week study (fish oil arm = 109; soybean oil arm = 107), 
dropped out before the 8 weeks (fish oil arm = 23; soybean oil = 11) and those who completed the 8‑week trial period and were included in the 
analysis (fish oil = 86; soybean oil = 96).The difference in completion between the two groups was, however, not significant at the end of study 
 (X2(1) = 1.64; p value = 0.20), and did not significantly influence the change in BDI‑II depressive symptom scores in fish oil (0.41 (95% CI − 4.49 to 
5.32), p = 0.87) and soybean oil (− 3.21 (95% CI − 13.18 to 6.76), p = 0.52) groups
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Table 1. The age distribution was similar in both groups 
with a median and interquartile range (median (IQR)) 
of 26 (22–30). The median (IQR) gestational age was 22 
(18–24) and 22 (19–24) weeks for fish oil and soybean 
oil groups, respectively. The total household income 
per month in Kenya Shillings was a median of 6000 
Table 1 Participants’ baseline characteristics by study group
**CD4 cell count levels: Fish oil—n = 108 (1 participant with missing CD4 was lost to follow-up)
Baseline characteristic Fish oil intervention group (N = 109) Soybean oil 
control group 
(N = 107)
Continuous variables (median (IQR))
 Age (single years) 26 (22–30) 26 (22–30)
 Gestation age (weeks) 22 (18–24) 22 (19–24)
 CD4 count (cells/mm3) 361 (287– 440) 360 (288–414)
 Weight (Kg) 60.5 (54.2–66.4) 62.0 (57.2–69.0)
 MUAC (cm) 26.0 (23.9–27.6) 26.0 (24.3–28.0)
 Household income per month (KSh) 6000 (3000–8000) 5025 (3000–8000)
 BDI‑II depressive symptom scores 20 (16–25) 21 (17–25)
Categorical variables (n (%))
 Age group (in years)
  Young = 15–25 53/109 (48.6) 48/107 (44.8)
  Not young 26–45 56/109 (51.4) 59/107 (55.1)
 Marital status
  Single (not married, divorced, widowed) 27/109 (24.8) 22/107 (20.6)
  Married 82/109 (75.2) 85/107 (79.4)
 Parity status
  First pregnancy 24/109 (22.0) 24/107 (22.4)
  Not a first pregnancy 85/109 (78.0) 83/107 (77.6)
 Education status
  No high school education 55/109 (50.4) 55/107 (51.4)
  At least high school education 54/109 (49.5) 52/107 (48.6)
 Employment status
  Not in gainful employment 61/109 (56.0) 64/107 (59.8)
  In gainful employment 48/109 (44.0) 43/107 (40.2)
 Household income status per month
  Below poverty line (less than Ksh.2913) 16/91 (17.5) 20/94 (19.4)
  At least on poverty line (at least Ksh.2913) 75/91 (82.4) 74/94 (78.7)
 Experienced stressful life events
  No stressful event 2 weeks before the study 73/109 (66.7) 75/107 (70.1)
  Had stressful event 2 weeks before the study 36/109 (33.0) 32/107 (30.0)
 CD4 cell count levels**
  Less than 350 cells/mm3 44/108 (40.7) 47/107 (43.9)
  350–500 cells/mm3 64/108 (59.3) 60/107 (56.1)
 Knew HIV status before pregnancy
  Newly tested (Less than 6 months) 56/109 (51.4) 56/107 (52.3)
  Known positive (KP) 6 months or more 53/109 (48.6) 51 (47.6)
 HIV status disclosure to anyone
  Status not disclosed to anyone 18/109 (16.5) 25/107 (23.4)
  Status disclosed to someone 91/109 (83.5) 82/107 (76.6)
 PMTCT support group meetings attendance
  Not attended support group meeting 62/109 (56.8) 54/107 (50.4)
  Attended support group meeting 47/109 (43.1) 53/107 (49.5)
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(3000–8000) for fish oil group and 5025 (3000–8000) for 
the soybean group. This was the income from the partici-
pant and her spouse, together with any other person liv-
ing with them. Based on this income level, the proportion 
of households that were below the poverty line, earning 
less than Kenya Shillings 2913, were also similar in the 
two groups with 17.5% in fish oil omega-3 and 19.4% in 
soybean oil group.
At least three-quarters of participants in each group 
were married and living with their spouse, and for more 
than 75% of them, this was not their first pregnancy 
(fish oil omega-3 = 78.7%; soybean = 78.3%,). It was also 
noted that participants had similar education status 
where those with at least high school education were 
49.5% in fish oil group and 48.6% in soybean oil group. 
Experiences of stressful life events 2  weeks prior to the 
study were also similar in both intervention arms (33.0% 
in fish oil and 30.0% in soybean oil group). The stress-
ors included knowledge of HIV status before pregnancy 
and disclosure (fish oil = 39.0%; soybean oil = 51.5%), 
domestic- and marital-related problems (fish oil = 25.0%; 
soybean = 45.0%) and financial-related issues (Fish 
oil = 36.1%; soybean oil = 3.0%).
Health‑related characteristics at baseline
At baseline, participants in both groups had mild to 
moderate and severe depressive symptoms (Fish oil: 
mild = 47/109 (43.1%); moderate = 46/109 (42.2%); 
severe = 16/109 (14.7%); soybean oil: mild = 46/107 
(43.0%); moderate = 48/107 (44.8%); severe = 13/107 
(12.1%).The minimum BDI-II symptom score in 
both groups was 14, while the maximum was 40, and 
the median scores were 20 (IQR = 16–25) and 21 
(IQR = 17–25) in fish oil intervention and soybean oil 
control groups, respectively. These baseline BDI-II scores 
were similar in the two study groups before randomiza-
tion. The CD4 cell count (cells/mm3) level was also simi-
lar for participants in both intervention arms. In fish oil 
omega-3 group, it was (median (IQR)) 361 (287–440) 
and in soybean oil group it was 360 (288–414) (p = 0.39). 
About half of participants from each intervention group 
(Fish oil = 51.4% had knowledge of their HIV status at 
least 6 months before the pregnancy, while the other half 
had been newly tested for HIV. More than 75% of them 
from each group had disclosed their status to a friend, a 
relative or husband.
Although all HIV-infected pregnant women were rou-
tinely invited by m2m peer educators to attend support 
group meetings as part of the PMTCT program, only 
47/109 (43.1%) and 53/107 (49.5%) of participants from 
fish oil and soybean oil reported to have attended these 
meetings. We observed that during these m2m support 
group meetings, the HIV-infected pregnant women 
received support and encouragement from the m2m peer 
educators and women who were either pregnant or had 
given birth with HIV infection. We also observed that 
these meetings involved sharing experiences of HIV-
infection, pregnancy and childcare, followed by a health 
talk by m2 m peer educators. It was further observed that 
sharing a meal at the end of the m2m health talk gave 
participants an opportunity to interact with each other 
and share their own experiences or listen to others.
Participants’ dietary nutrient intake at baseline
The dietary nutrient intake values from the reported 
foods and the proportion of study population report-
ing consumption levels below the Estimated Average 
Requirements (EAR) for pregnant women are as listed 
in Table  2. At baseline, the median nutrient intake was 
below the EAR for pregnant women for all nutrients con-
sumed by participants in each of the study groups. The 
intake values were least for omega-3 EPA and DHA fatty 
acids whose median (IQR) values were zero in the Fish 
oil group and 0 (0–0.01) grams in the Soybean oil group. 
More than 60.0% of participants from each intervention 
arm had their dietary nutrient intake levels below the 
EARs for pregnant women for most nutrients.
Effect of fish oil omega‑3 EPA‑rich supplements 
on change in BDI‑II depressive symptom scores 
among HIV‑seropositive pregnant women
Normality tests for change in BDI‑II scores by study arm
Based on the Shapiro–Wilk statistical test of normal-
ity, the change in BDI-II depressive symptom scores 
was normally distributed at week four after interven-
tion (fish oil: w = 0.97, p = 0.07; soybean oil: w = 0.98, 
p = 0.13) and week eight after intervention (fish oil: 
w = 0.98, p = 0.35; soybean oil: w = 0.98, p = 0.24). Fur-
ther statistical test for normality with normal quantile 
plot (q-plot) also confirmed that the change in baseline 
scores was normally distributed within each group at 
4 weeks and after 8 weeks (Fig. 2).The change in BDI-II 
depressive symptom scores was normally distributed 
4  weeks after intervention (fish oil: w = 0.97, p = 0.07; 
soybean oil: w = 0.98, p = 0.13) and 8  weeks after inter-
vention (fish oil: w = 0.98, p = 0.35; soybean oil: w = 0.98, 
p = 0.24). Any variability present in the distribution of 
the scores in the samples was not statistically signifi-
cant, based on Levene’s test of variance at 4  weeks for 
sample means (F (1188) = 0.79, p = 0.37) and medians (F 
(1180) = 0.80, p = 0.37). The variability in the distribu-
tion of data was also not statistically significant at week 
eight for sample means, (F (1180) = 1.96 p = 0.16), medi-
ans (F (1180) = 1.45, p = 0.23) and standard deviation 
test of variance (p = 0.24). Any difference in variability 
in errors across observations was controlled through 
Page 9 of 16Opiyo et al. Ann Gen Psychiatry           (2018) 17:49 
robust analysis method. These statistical tests proved that 
the primary outcome data of the study, change in BDI-II 
depressive symptom scores, met the regression analysis 
assumptions of normality.
Change in BDI‑II scores before adjusting for baseline 
covariates
At the end of the trial, at week 8, most participants 
in both arms had mild depressive symptoms (Fish 
oil = 82/86 (95.3%), Soybean oil = 94/96 (97.9%)) with a 
minimum BDI-II score of 19 compared to 14 at baseline. 
The difference in the proportions of participants with dif-
ferent BDI-II depressive symptom levels after 8 weeks of 
intervention was not significantly different between the 
two intervention arms  (X2 = 3.1, d.f = 2, p value = 0.21).
Table  3 shows the mean change and mean difference 
in change in BDI-II scores before adjusting for base-
line covariates at 4 and 8 weeks post intervention. After 
4  weeks, fish oil intervention group had a mean (SD) 
change in BDI-II depressive symptom scores of − 10.8 
(± 7.3) with a 95% confidence interval (CI) of − 12.3 to 
− 9.3 scores. The mean (SD) change in scores after the 
4  weeks for the soybean oil control group was − 11.5 
(± 6.5) with a 95% CI of − 12.3 to − 10.2 scores. At the 
end of the 8-week study period, participants in the fish 
oil intervention group had a mean (SD) change in BDI-
II depressive symptom scores of − 13.3 (± 7.4) with a 
95% CI of − 14.9 to − 12.0 scores. The mean (SD) change 
in scores among soybean oil control group was − 13.9 
(± 6.5) with a 95% CI of − 15.3 to − 12.6 scores.
The mean difference in the change in BDI-II scores 
between the two intervention groups was 0.7 (Standard 
Error = 1.0) with a 95% CI 1.3 to 2.7 after 4  weeks and 
0.6 (Standard Error = 1.0) with a 95% CI 1.5 to 2.6 after 
8  weeks of intervention. These differences in change in 
BDI-II scores were, however, not significantly different 
(week 4: p = 0.49; week 8: p = 0.58) as seen in Table  3. 
By fitting simple linear regression model, the interven-
tion could only explain 0.25% of the variability in change 
in depressive symptom scores at week four  (R2 = 0.0025) 
and 0.07%  (R2 = 0.0017) at week eight. The intervention 
alone was not statistically significant in explaining the 
variability in change in BDI-II scores at week four 4 (F 
(1188) = 0.47, p = 0.49) and week eight (F (1180) = 0.31; 
p = 0.58).
The calculated 95% CI for the two groups overlapped 
substantially at week four and week eight when the 
median scores were compared (Fig.  3), suggesting that 
there was no significant difference in intervention effect 
on depressive symptoms between the two study groups.
Analysis of change in BDI‑II scores between groups
All baseline attributes held constant, the change in BDI-
II scores at week four were 0.16 (95% CI − 1.48 to 1.81) 
and at week eight, 1.01 scores (95% CI (− 0.58 to 2.60) 
times higher in fish oil intervention group than in soy-
bean oil control group (Table 4). This intervention effect 
was, however, not statistically significant at both week 4 
(p = 0.84) and week 8 (p = 0.21). The baseline characteris-
tics in the ANCOVA model explained 48.8%  (R2 = 0.488) 
and 56.9%  (R2 = 0.569) of the variance in changes in 
Table 2 Dietary nutrient intake levels reported at baseline
a EAR: Estimated Average Requirements were computed by dividing the recommended dietary allowances (RDAs) for pregnant women by the corresponding 
conversion factor for each nutrient
b Iron: Median dietary intake values for iron were computed at bioavailability levels of 15%
Nutrient Estimated average 
requirements (EAR)
Baseline nutrient intake levels (median (IQR)) and proportions of participants with less than 
 EARa levels for pregnant women













Vitamin C (mg) 71 63.5 (15.0–121.6) 62/109 (56.9) 61.5 (15.1–191.2) 59/107 (55.1)
Vitamin B1 (mg) 1.2 0.8 (0.2–1.8) 73/109 (67.0) 0.7 (0.2–1.8) 67/107 (62.6)
Vitamin B6 (mg) 1.6 0.7 (0.3–1.4) 85/109 (78.0) 0.7 (0.4–1.3) 86/107 (80.4)
Vitamin B12 (mcg) 2.6 0.5 (0–1.4) 97/109 (89.0) 0.4 (0–1.4) 94/107 (87.8)
Folate (mcg) 520 106.4 (46.2–302.7) 98/109 (89.9) 178 (23.7–360.0) 91/107 (85.0)
Iron (mg)b 22.0 1.8 (0.6–3.6) 109/109 (100) 2.3 (1.1–3.2) 107/107 (100)
Vitamin E (IU) 12.5 4.6 (2.5–8.6) 89/109 (81.6) 4.7 (2.0–9.6) 87/107 (81.3)
Calcium (mg) 833 411.0 (238.1–916.1) 78/109 (71.2) 448.8 (206.5–930.6) 79/107 (73.8)
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Normality q-plot for change in BDI-II scores after 8 weeks:N=96
Fig. 2 Quantile–quantile plot normality test for change in BDI‑II scores by study arm The quantile–quantile plot normality statistical test for 
change in BDI‑II depressive symptom scores conducted showed that the scores were normally distributed after 4 weeks: fish oil, N = 92; soybean 
oil, N = 98; and after 8 weeks: fish oil, N = 86; soybean oil—N = 96). Any variability present in the distribution of the scores in the samples was not 
statistically significant, based on Levene’s test of variance for sample means of the change in scores after 4 weeks (F (1188) = 0.79, p = 0.37; medians 
(F (1180) = 0.80, p = 0.37) and after 8 weeks (F (1180) = 1.96 p = 0.16); medians (F (1180) = 1.45, p = 0.23) and standard deviation test of variance 
(p = 0.24). Variability in errors across observations was controlled for through robust analysis method. Hence, the change in BDI‑II depressive 
symptom scores met the regression analysis assumptions of normality
Table 3 Change in BDI-II scores after intervention
SD standard deviation
Intervention period Intervention group Change in BDI‑II scores 
(Mean (SD, 95% CI)
Difference between groups in change 
in BDI‑II scores (Mean (SE, 95% CI)
Statistical test
t df p
After 4 weeks Fish oil (N = 92) − 10.8 (− 12.3 to − 9.3) 0.7 (1.0, − 1.3 to 2.7) 0.69 188 0.49
Soybean oil (N = 98) − 11.5 (− 12.3 to − 10.2)
After 8 weeks Fish oil (N = 86) − 13.3 (− 14.9 to − 12.0) 0.6 (1.0, − 1.5 to 2.6) 0.55 180 0.58
Soybean oil (N = 96) − 13.9 (− 15.3 to − 12.6)
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BDI-II depressive symptoms scores at week 4 and week 
8, respectively.
At week 4, the change in BDI-II depressive symptom 
scores was significantly associated with baseline BDI-
II scores, − 0.77 (95% CI − 0.94 to − 0.61, p = 0.000), 
dietary omega-3 intake − 3.03 (95% CI − 5.41 to − 0.66, 
p = 0.012), dietary vitamin B1 intake − 3.46 (95% CI 
− 5.46 to − 1.48, p = 0.001), attendance in PMTCT 
m2 m support group meetings 2.06 (95% CI 0.38 to 3.74, 
p = 0.02), vitamin B6 2.84 (95% CI 0.24 to 5.42, p = 0.03) 
and zinc-2.60 (95% CI − 4.42 to − 0.78, p = 0.01). The 
presence of interaction between baseline BDI-II depres-
sive symptom scores and these variables that were sig-
nificantly associated with change in BDI-II scores was 
tested. There was no interaction between the baseline 
BDI-II scores and any of the variables, suggesting that 
each variable influenced the change in BDI-II scores 
independently.
At the end of the study at week 8, change in BDI-II 
depressive symptom scores was significantly associ-
ated with baseline BDI-II symptom scores − 0.87 (95% 
CI − 1.02 to − 0.72; p = 0.000) as seen on Table  4. The 
change in the depressive symptom scores was slightly 
more than two times higher, 2.24 (95% CI − 0.04 to 4.51; 
p = 0.05) among participants who met the estimated 
average requirements for Vitamin B6 dietary intake 
at baseline. The change was also more than five times 
higher, 5.39 (95% CI 0.63 to 10.14, p = 0.03) among those 
participants who met the estimated average requirement 
for their dietary zinc intake at baseline, assuming that 
all other variables were held constant in the ANCOVA 
model. Dietary iron intake was, however, omitted in the 
analysis because all participants in both study groups 
(Fish oil: 109/109 and soybean oil: 107/107) had their 
intake levels below the recommended EAR values. The 
presence of interaction between baseline BDI-II depres-
sive symptom scores and dietary zinc and vitamin B6 
intake was tested. There was no interaction between the 
baseline BDI-II scores and any of the two variables and 
each variable influenced the change in the BDI-II scores 
independently.
Adverse events
Both known and unknown possible adverse events were 
closely monitored throughout the 8-week study period 
for each participant by phone or face-to-face individ-
ual interviews and observations. There were no serious 
adverse events reported by participants from either of 
the groups. However, some participants reported that 
they occasionally experienced unpleasant feelings as 
shown on Table 5.
Discussion
In this study, we tested the hypothesis that there is no 
difference in the magnitude of change in BDI-II scores 
between HIV-seropositive pregnant women with depres-
sive symptoms taking fish oil omega-3 EPA-rich sup-
plements and the control group taking soybean oil soft 
gels. We had hypothesized to detect as statistically sig-
nificant at 5% level (α = 0.05) a true difference of at least 
4 BDI-II scores, equivalent to a 20% change, between the 
intervention and control group. All participants were 
randomized at same level in terms of their demographic, 
socio-economic, dietary, depressive symptoms and other 
health-related attributes. Any imbalance that might have 
occurred was therefore due to chance alone. At the end 
of the 8-week trial period, each group experienced a 
20% change (4 units) in BDI-II scores. The differences in 
reduction in BDI-II scores were 0.7 and 0.6 times more 
in the fish oil intervention group than in the soybean 
oil control group at week four and week eight, respec-
tively. These differences were not statistically significant. 
The fish oil intervention alone could only explain 0.25% 
and 0.07% of the variability at week four and week eight, 
respectively. The change in BDI-II depressive symptom 
scores was only 0.14 (95% CI − 1.51 to 1.78) times higher 
at week four and 1.01 scores (95% CI (− 0.58 to 2.60) 
times higher at week eight in fish oil intervention group 
than in soybean oil control group. The statistical change 
in the BDI-II scores could not be explained by either fish 




































Fig. 3 95% confidence interval bars for change in BDI‑II scores by 
study arm and period. The calculated 95% confidence intervals (CI) 
for the mean difference in the change in BDI‑II scores between the 
two intervention groups overlapped substantially after 4 weeks (Fish 
oil (N = 92). 95% CI − 12.3 to − 9.3; soybean oil (N = 98), 95% CI − 12.3 
to − 10.2) and after 8 weeks (Fish oil (N = 86), 95% CI − 14.9 to − 12.0; 
soybean oil (N = 96), 95% CI − 15.3 to − 12.6). This overlap suggested 
that there was no significant difference in intervention effect on 
depressive symptoms between the two study groups
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Our study demonstrated that there is no difference 
in the magnitude of change in BDI-II scores between 
HIV–seropositive pregnant women with depressive 
symptoms taking fish oil omega-3 EPA-rich supplements 
with a daily dosage of 3.17 grams (EPA = 2.15 grams; 
DHA = 1.02 grams) and a control group taking soybean 
oil of a daily dosage of saturated fatty acids (0.53 grams), 
monounsaturated fatty acids (0.89 grams) and polyunsat-
urated fatty acids (0.985 grams) with traces of EPA (0.34 
grams). Based on this, we conclude in this study that the 
fish oil omega-3 is not effective in reduction of depres-
sive symptoms among HIV-infected pregnant women 
with mild, moderate and severe depression symptoms. 
The fish oil omega-3 supplements were, however, well 
Table 4 ANCOVA analysis of mean change in BDI-II scores by baseline characteristics and intervention duration
* Baseline variables that were significantly associated with the change in BDI-II depressive symptom scores at week 4 and week 8
Baseline characteristics Duration of intervention
Week 4 Week 8
Regression coefficient (95% CI) p value Regression coefficient (95% CI) p value
Intervention group 0.40 (− 1.25 to 2.05) 0.63 1.00 (− 0.58 to 2.60) 0.21
Baseline BDI‑II scores − 0.79 (− 0.94 to − 0.64) 0.00* − 0.87 (− 1.02 to − 0.73) 0.00*
Age (single years) 0.02 (− 0.16 to 0.21) 0.82 0.11 (− 0.06 to 0.28) 0.21
Gestational age (months) 0.03 (− 0.21 to 0.26) 0.83 0.04 (− 0.17 to 0.25) 0.69
CD4 cell count (cells/mm3) 0.01 (− 0.00 to 0.01) 0.12 − 0.001 (− 0.01 to 0.01) 0.62
Employment − 0.85 (− 2.79 to 1.09) 0.39 − 58 (− 2.19 to 1.05) 0.47
Knew HIV status when pregnant − 1.54 (− 3.33 to 0.26) 0.09 − 0.83 (− 2.71 to 1.02) 0.37
HIV status disclosure − 1.16 (− 3.09 to 0.76) 0.24 − 0.49 (− 2.22 to 1.22) 0.57
Marital status 1.03 (− 1.02 to 3.08) 0.32 0.84 (− 0.98 to 2.66) 0.36
Education level − 0.51 (− ‑2.37 to 1.35) 0.59 − 0.40 (− 2.09 to 1.29) 0.64
Parity − 0.99 (− 2.06 to 1.86) 0.92 − 1.92 (− 4.10 to 0.26) 0.08
Stressful life event − 0.19 (− 1.99 to 1.62) 0.84 1.01 (− 0.48 to 2.59) 0.18
PMTCT m2 m meetings 2.04 (0.37 to 3.70) 0.02* 1.09 (− 0.44 to 2.65) 0.16
MUAC (cm) 0.03 (− 0.34 to 0.39) 0.87 − 0.38 (− 0.35 to 0.27) 0.81
Dietary omega‑3 − 2.98 (− 5.32 to − 0.64) 0.01* − 0.32 (− 2.25 to 1.97) 0.89
Dietary vitamin C − 0.85 (− 2.70 to 0.99) 0.36 0.94 (− 0.97 to 2.85) 0.33
Dietary vitamin B1 − 3.26 (− 5.21 to − 1.31) 0.001* − 1.41 (− 3.65 to 0.83) 0.22
Dietary vitamin B6 2.27 (− 0.37 to 4.91) 0.09 2.24 (− 0.04 to 4.51) 0.05*
Dietary vitamin B12 0.07 (− 2.42 to 2.57) 0.95 − 0.63 (− 2.80 to 1.56) 0.57
Dietary folate 0.62 (− 2.02 to 3.27) 0.64 1.44 (− 1.29 to 4.18) 0.30
Dietary vitamin E − 0.59 (− 3.27 to 2.09) 0.66 − 1.29 (− 3.19 to 0.62) 0.18
Dietary zinc 8.67 (− 4.49 to 21.8) 0.19 5.39 (0.64 to 10.14) 0.03*
Dietary selenium 1.23 (− 1.20 to 3.66) 0.32 1.84 (− 0.25 to 3.94) 0.08
Dietary calcium 1.23 (− 0.72 to 3.27) 0.21 − 1.64 (− 3.60 to 032) 0.10
Table 5 Participants reporting unpleasant feelings by study arm and period
Other adverse events (not serious) experienced Soybean oil Fish oil
Total reported 15/107 (14.02%) 24/109 (22.02%)
Occasionally nauseated with fishy‑after‑taste 5/107 (4.67%) 10/109 (9.17%)
Occasional vomiting in the morning after taking soft gel 3/107 (2.8%) 6/109 (5.5%)
Occasional heartburn 5/107 (4.67%) 3/109 (2.75%)
Occasional bloated stomach 0/107 (0%) 2/109 (1.83%)
Occasional loose stool 1/107 (0.93%) 0/109 (0%)
Occasional itchy skin 1/107 (0.93%) 2/109 (1.83%)
Nose bleeding once 0/107 (0%) 1/109 (0.92%)
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tolerated, without serious adverse side effects among 
HIV-infected pregnant women.
Several possible explanations could have contributed to 
the observed lack of a statistically significant difference 
in the change in BDI-II scores between the fish oil inter-
vention group and the soybean oil control group. First, 
in this study, participants had mild, moderate and severe 
depressive symptoms at baseline while previous studies 
had only participants with major depressive symptoms. 
Second, the previous studies on omega-3 supplementa-
tion were conducted among pregnant women without 
HIV infection. Even though the prevalence of depression 
in HIV-infected pregnant women has been documented 
before [11, 13, 53, 54], change in depressive symptoms 
scores following omega-3 EPA-rich fatty acid supple-
mentation had not been previously demonstrated in this 
population group. Yet, in HIV-infected pregnant women, 
the omega-3 EPA and DHA fatty acid absorption may be 
impaired [14, 55] due to reduced activity of the pancre-
atic lipase enzyme [56], thus contributing to low response 
to the fish oil omega-3 fatty acid supplementation.
The third explanation for lack of a statistically signifi-
cant difference in change in BDI-II scores between the 
groups could have been the “placebo effect”. Due to the 
“placebo effect”, some participants in the soybean oil con-
trol group believed that they were taking fish oil soft gels 
and reported a reduction in their depressive symptom 
scores might have contributed to the observed lack of a 
significant statistical difference between the intervention 
and control group. Both the fish oil soft gels for the inter-
vention group and soybean oil for the control group were 
physically similar in shape and color. This “placebo effect” 
might have influenced the mean change in BDI-II depres-
sive symptom scores of the groups, causing “regression 
to the mean” value, where the mean change in depressive 
symptom scores showed a trend towards the treatment 
effect [57]. “Regression to the mean” was controlled in 
this study through the ANCOVA analysis model, which 
adjusted for any extreme baseline values and variability 
during analysis.
The fourth possible explanations for lack of a statisti-
cally significant difference in change in BDI-II scores 
between the fish oil intervention group and the soybean 
oil control group in this study was the intensive follow-
ups of participants throughout the study period which 
could have contributed to “Hawthorn Effect”. McCarney 
and colleagues demonstrated that intensive follow-up of 
participants resulted in a better outcome in clinical trial 
than minimal follow-up, and they defined “Hawthorn 
Effect” as increase in treatment response due to psycho-
logical stimulus of being singled out and being made to 
feel important [58]. Regular follow-ups of all participants 
in both study groups after every 2 weeks to re-supply the 
treatment, and regular cell-phone contacts for purposes 
of monitoring adherence in taking the treatment might 
have made the HIV-infected pregnant feel worthwhile 
and more positive about their pregnancy outcome. The 
findings on depressive symptoms revealed that the symp-
tom of worthlessness was reported by more than 60% of 
participants from intervention and control group at base-
line, but less than 25% of participants from each group at 
the end of the study. This is an indication that more than 
75% of participants had their BD-II score for the symp-
tom of worthlessness reduced at the end of the study. 
Although routine PMTCT-m2m peer education meet-
ing attendance did not significantly statistically influ-
ence the change in BDI-II scores, its activities might have 
also contributed to the positive response and feeling of 
“important” exhibited by participants during follow-ups 
in both study groups. It was not possible to control for 
the Hawthorn Effect. Regular follow-up of participants in 
this study was, however, necessary to re-supply the inter-
vention and monitor compliance in the trial.
Although there was no significant difference in base-
line BDI-II scores between the intervention and con-
trol groups before randomization, participants who had 
higher BDI-II scores at baseline experienced less change 
in their depressive scores than those who had lower 
scores. The findings suggest that severity of depressive 
symptoms was a predictor of the magnitude of change in 
BDI-II depressive symptoms scores rather than the fish 
oil omega-3 intervention. These findings on severity of 
baseline depressive symptom scores influencing change 
in the scores after intervention support the observation 
made by Kilt and colleagues that response to depression 
treatment decreased with increasing baseline symptom 
severity [59]. These research findings highlight the need 
for routine screening for depressive symptoms to guide 
timely identification and management of depressive 
symptoms in HIV-infected pregnant women.
Strengths and weaknesses of the study
To our knowledge, this was the first study to explore 
the effect of fish oil omega-3 fatty acids on depression 
among HIV-infected pregnant women. It examined 
change in individual pregnant women’s BDI-II depres-
sive symptom scores before and after the interven-
tion with fish oil omega-3 EPA-rich supplement. Most 
potential confounding demographic, socio-economic 
and health-related factors were controlled for during 
the study design by the randomization. The ANCOVA 
analysis model used in analyzing the study outcome 
further controlled for any imbalance due to baseline 
variations. Other baseline covariates which were most 
likely to change over the intervention period such as 
BDI-II depressive symptom scores, CD4 cell count 
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levels, frequency of interaction with PMTCT peer edu-
cators, occurrence of stressful life events and omega-3 
fatty acid levels in the body were controlled for in the 
ANCOVA analysis model.
The other strength of this study was the use of BDI-
II tool which contains depressive symptoms exhibited 
in both HIV and pregnancy conditions. Our statistical 
reliability test for the BDI-II scale in assessing depres-
sive symptoms in HIV-infected pregnant women con-
firmed that the tool was reliable. The types of depressive 
symptoms exhibited in pregnancy and HIV infection 
that were reported by a sub-sample of HIV-infected 
pregnant women and health workers prior to base-
line data collection for the main study also confirmed 
that the local understanding of depressive symptoms 
matched with the symptoms listed on the BDI-II tool. 
Furthermore, the use of BDI-II tool in screening for 
depressive symptoms had been previously validated in 
other studies among adults, pregnant women and HIV-
infected individuals and in the African context [60–62].
Our study findings may not be generalized to other 
populations who are neither pregnant nor HIV sero-
positive. This is for two reasons. First, participants were 
depressed partly because of their HIV condition, preg-
nancy or a combination of both HIV and pregnancy. 
However, the BDI-II depressive symptom screening 
tool used in this study comprises of a comprehensive 
list of symptoms that are exhibited in both pregnancy 
and HIV infection. Second, pregnancy and HIV infec-
tion on their own are also associated with nutrient 
depletion and increased nutrient demand. This implies 
that the recommended EARs for pregnancy alone are 
not adequate for pregnancy and HIV infection condi-
tions. This research, however, contributes to the ongo-
ing debate on the effect of fish oil omega-3 fatty acids 
in reduction of depressive symptoms among pregnant 
women in the context of HIV infection. Further larger 
studies with a higher dose of fish oil supplements with-
out soybean oil for control groups should be explored, 
particularly among the severely depressed women from 
this vulnerable population in future studies. Such stud-
ies in future should also consider controlling for the 
“Hawthorn effect” throughout the study period.
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